{
  "Disease": [
    {"role": "user", "content": "Please identify the \"Disease\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Disease\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: Twelve asthmatic patients ( FEV1 , 81 + / - 4 % predicted ) , requiring only occasional inhaled beta - agonists as their sole therapy , were given a 14 - day treatment with high dose inhaled salbutamol ( HDS ) , 4 , 000 micrograms daily , low dose inhaled salbutamol ( LDS ) , 800 micrograms daily , or placebo ( PI ) by metered - dose inhaler in a double - blind , randomized crossover design .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| Asthma |\n\nIn this paragraph, the only mentioned disease is Asthma. The patients are identified as having Asthma and being treated for it with various therapies."},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Disease\" and present the valid entities as a Markdown table with one column \"Disease\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| Asthma |\n\nIn this paragraph, the only mentioned disease is Asthma. The patients are identified as having Asthma and being treated for it. The other entities mentioned, such as FEV1, HDS, LDS, and PI, do not clearly refer to diseases."}
  ],
  "Chemical": [
    {"role": "user", "content": "Please identify the \"Chemical\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Chemical\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: Twelve asthmatic patients ( FEV1 , 81 + / - 4 % predicted ) , requiring only occasional inhaled beta - agonists as their sole therapy , were given a 14 - day treatment with high dose inhaled salbutamol ( HDS ) , 4 , 000 micrograms daily , low dose inhaled salbutamol ( LDS ) , 800 micrograms daily , or placebo ( PI ) by metered - dose inhaler in a double - blind , randomized crossover design .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| salbutamol |\n| inhaled salbutamol (high dose) |\n| inhaled salbutamol (low dose) |\n| FEV1 (Forced Expiratory Volume in 1 second) |\n| predicted |\n\nExplanation:\nThe paragraph mentions \"twelve asthmatic patients\" and \"requiring only occasional inhaled beta-agonists as their sole therapy\". The specific beta-agonist used in the study is identified as \"salbutamol\" which is given in two different doses: high dose (4,000 micrograms daily) and low dose (800 micrograms daily). The paragraph also mentions \"FEV1 (Forced Expiratory Volume in 1 second)\" which is a measure of lung function."},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Chemical\" and present the valid entities as a Markdown table with one column \"Chemical\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| salbutamol |\n| inhaled salbutamol (high dose) |\n| inhaled salbutamol (low dose) |\n\nExplanation:\nThe paragraph mentions \"twelve asthmatic patients requiring only occasional inhaled beta-agonists as their sole therapy\". The specific beta-agonist used in the study is identified as \"salbutamol\" which is given in two different doses: high dose (4,000 micrograms daily) and low dose (800 micrograms daily). Therefore, \"salbutamol\", \"inhaled salbutamol (high dose)\", and \"inhaled salbutamol (low dose)\" are the valid chemical entities in the paragraph.\n\nOther entities mentioned in the paragraph, such as \"twelve asthmatic patients\" and \"FEV1 (Forced Expiratory Volume in 1 second)\" do not clearly refer to chemicals and are not included in the table."}
  ]
}